Upgrade to SI Premium - Free Trial

UBS Reiterates Buy Rating on Neurocrine Bio. (NBIX) Following Reports of Soleno Acquisition

April 6, 2026 9:35 AM
UBS analyst Ashwani Verma reiterated a Buy rating and $161.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented, "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments

Next Articles